NASDAQ · PYPD
PolyPid Ltd.
$5.59-$0.19 (-3.29%)
PolyPid Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.28% below the high.
Loading market information…
NASDAQ · ECOR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
electroCore, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
electroCore, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.27. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow electroCore, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 7, 2025 |
| -$0.47+16.07% vs estimate |
| $6.72M-3.03% vs estimate |
| Q4 2024 | Mar 12, 2025 | -$0.40-17.65% vs estimate | $7.05M-0.13% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.31-6.9% vs estimate | $6.55M+0.99% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.59-$0.19 (-3.29%)
PolyPid Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.28% below the high.
$1.18+$0.02 (+1.72%)
MAIA Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.01% below the high.
$1.49+$0.07 (+4.56%)
RenovoRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.47% below the high.
$3.51+$0.51 (+16.83%)
Hyperion DeFi, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.95% below the high.
$1.30+$0.04 (+3.17%)
Myomo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.22% below the high.
$2.98+$0.01 (+0.34%)
111, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.32% below the high.
$0.97+$0.11 (+12.96%)
NeuroOne Medical Technologies Corporation’s quoted price sits in the lower half of its reported 52-week range, 84.15% below the high.
$0.13+$0.07 (+140.38%)
Zynex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.52% below the high.
